Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery.

Victor Jimenez Yuste Emérito Carlos Rodríguez MerchánTadashi MatsushitaPål Andrè Holme

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)

The current evidence base indicates that surgery can be successfully performed in patients with inhibitors who are receiving emicizumab and that bypassing agents can be used concomitantly. Data from prospective studies are required to further support recommendations for haemostatic management of surgery in patients receiving emicizumab.

Keyphrases

minimally invasive
coronary artery bypass
surgical site infection
electronic health record
big data
percutaneous coronary intervention
coronary artery disease
atrial fibrillation
acute coronary syndrome
artificial intelligence